Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Trojano

Showing results (101-110 of 342) with videos related to

Pageof 35
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 30, 2003
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern ItalyMaria Trojano, Maria Liguori, Damiano Paolicelli, et al.
Multiple Sclerosis and Related Disorders|June 4, 2018
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term settingMaria Trojano, Helmut Butzkueven, Ludwig Kappos, et al.
Journal of the Neurological Sciences|October 8, 2005
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosisCarla Tortorella, Alessandra Bellacosa, Damiano Paolicelli, et al.
Journal of Neurology|August 10, 2025
The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensusMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Journal of Neuroimmunology|February 29, 2012
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosisMariantonietta Caragnano, Paola Tortorella, Alessandra Bergami, et al.
Neurology|February 19, 2016
The challenge of comorbidity in clinical trials for multiple sclerosisRuth Ann Marrie, Aaron Miller, Maria Pia Sormani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 25, 2017
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosisCarla Tortorella, Vita Direnzo, Maddalena Ruggieri, et al.
Journal of Neurology|May 24, 2022
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 15, 2020
Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri<sup>®</sup> Observational Program (TOP)Helmut Butzkueven, Maria Trojano, Ludwig Kappos, et al.
Journal of Neurology|September 22, 2022
Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Pageof 35

Showing results (101-110 of 342) with videos related to

Sort By:
Pageof 35
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 30, 2003
Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern ItalyMaria Trojano, Maria Liguori, Damiano Paolicelli, et al.
Multiple Sclerosis and Related Disorders|June 4, 2018
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term settingMaria Trojano, Helmut Butzkueven, Ludwig Kappos, et al.
Journal of the Neurological Sciences|October 8, 2005
Age-related gadolinium-enhancement of MRI brain lesions in multiple sclerosisCarla Tortorella, Alessandra Bellacosa, Damiano Paolicelli, et al.
Journal of Neurology|August 10, 2025
The use of high-efficacy disease-modifying therapies in multiple sclerosis: recommendations from an expert Delphi consensusMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Journal of Neuroimmunology|February 29, 2012
Monocytes P2X7 purinergic receptor is modulated by glatiramer acetate in multiple sclerosisMariantonietta Caragnano, Paola Tortorella, Alessandra Bergami, et al.
Neurology|February 19, 2016
The challenge of comorbidity in clinical trials for multiple sclerosisRuth Ann Marrie, Aaron Miller, Maria Pia Sormani, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 25, 2017
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosisCarla Tortorella, Vita Direnzo, Maddalena Ruggieri, et al.
Journal of Neurology|May 24, 2022
Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|May 15, 2020
Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri<sup>®</sup> Observational Program (TOP)Helmut Butzkueven, Maria Trojano, Ludwig Kappos, et al.
Journal of Neurology|September 22, 2022
Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinionMassimo Filippi, Maria Pia Amato, Diego Centonze, et al.
Pageof 35